Correlation Between Oncolytics Biotech and Spectral Med

Can any of the company-specific risk be diversified away by investing in both Oncolytics Biotech and Spectral Med at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncolytics Biotech and Spectral Med into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oncolytics Biotech and Spectral Med, you can compare the effects of market volatilities on Oncolytics Biotech and Spectral Med and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncolytics Biotech with a short position of Spectral Med. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncolytics Biotech and Spectral Med.

Diversification Opportunities for Oncolytics Biotech and Spectral Med

-0.31

Correlation Coefficient

Oncolytics Biotech  Spectral Med

Very good diversification

The 3 months correlation between Oncolytics and Spectral is -0.31. Overlapping area represents the amount of risk that can be diversified away by holding Oncolytics Biotech and Spectral Med in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spectral Med and Oncolytics Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncolytics Biotech are associated (or correlated) with Spectral Med. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spectral Med has no effect on the direction of Oncolytics Biotech i.e., Oncolytics Biotech and Spectral Med go up and down completely randomly.

Pair Corralation between Oncolytics Biotech and Spectral Med

Assuming the 90 days trading horizon Oncolytics Biotech is expected to under-perform the Spectral Med. But the stock apears to be less risky and, when comparing its historical volatility, Oncolytics Biotech is 1.27 times less risky than Spectral Med. The stock trades about -0.29 of its potential returns per unit of risk. The Spectral Med is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  58.00  in Spectral Med on September 4, 2024 and sell it today you would lose (3.00) from holding Spectral Med or give up 5.17% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Oncolytics Biotech  vs.  Spectral Med

Oncolytics Biotech

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oncolytics Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy fundamental indicators, Oncolytics Biotech is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Spectral Med

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Spectral Med has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Oncolytics Biotech and Spectral Med

The main advantage of trading using opposite Oncolytics Biotech and Spectral Med positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncolytics Biotech position performs unexpectedly, Spectral Med can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spectral Med will offset losses from the drop in Spectral Med's long position.

The idea behind Oncolytics Biotech and Spectral Med pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.